
MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target
MoonLake Immunotherapeutics (MLTX) Analyst Ratings
Bulls say
MoonLake Immunotherapeutics demonstrates a positive outlook due to the robust Phase II data for SLK in the treatment of hidradenitis suppurativa (HS) and other inflammatory conditions, which is anticipated to yield a superior profile in the upcoming Phase III trials. The company's innovative SLK Nanobody, which targets both IL-17A and IL-17F, shows promising efficacy compared to existing treatments like Cosentyx, further supported by strong feedback from key opinion leaders regarding its potential in early-line moderate-to-severe HS. Additionally, the growing market awareness and documented unmet needs in HS, alongside the potential for SLK in other indications, suggest meaningful upside opportunities for MoonLake's stock.
Bears say
MoonLake Immunotherapeutics faces significant risks that contribute to a negative outlook on its stock, primarily revolving around the potential for unexpected safety events and efficacy challenges that could disrupt ongoing clinical trials and lower the likelihood of successful drug development. In addition, the company's recent 4Q24 net loss of $44.2 million reflects its financial strain, further exacerbated by the risks associated with regulatory approvals, which could severely limit revenue generation opportunities. Furthermore, the low placebo response rates observed in clinical trials and the potential lack of differentiation from competitors may hinder market adoption and success in a competitive landscape.
This aggregate rating is based on analysts' research of MoonLake Immunotherapeutics and is not a guaranteed prediction by Public.com or investment advice.
MoonLake Immunotherapeutics (MLTX) Analyst Forecast & Price Prediction
Start investing in MoonLake Immunotherapeutics (MLTX)
Order type
Buy in
Order amount
Est. shares
0 shares